The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures

We report the psychometric properties of multiple outcome measures from these two tests as well as their correlations with standard neuropsychological measures and functional capacity measures

Michael S. Kraus; James M. Gold; Deanna M. Barch; Trina M. Walker; Charlotte A. Chun; Robert W. Buchanan; John G. Csernansky; Donald C. Goff; Michael F. Green; L. Fredrik Jarskog; Daniel C. Javitt; David Kimhy; Jeffrey A. Lieberman; Joseph P. McEvoy; Raquelle I. Mesholam-Gately; Larry J. Seidman; M. Patricia Ball; Robert S. Kern; Robert P. McMahon; James Robinson; Stephen R. Marder; Richard S.E. Keefe

2019

Scholarcy highlights

  • Cognitive impairments are a core feature of schizophrenia and a major determinant of poor functional outcome
  • Because of the history of clinical NP test development, with a focus on broad sensitivity to impairment, the standard NP tests chosen for the MATRICS Consensus Cognitive Battery are likely to be limited in their sensitivity to specific cognitive functions mediated by discrete neurobiological processes
  • In addition to the MCCB and SCoRS, cognition was assessed by two tests that have been found to activate prefrontal cortical function, the AX-Continuous Performance Task and N-back, as a pilot study found that patients receiving MK-077 showed improvement on these measures
  • The cognitive neuroscience measures investigated in this study are more time-consuming and burdensome than standard neuropsychological tests
  • AX-CPT tests were flagged for review if any of the following were true: the participant failed to respond to 20% or more of trials, missed all BX trials, missed > 25% of BY trials or failed to score significantly above chance on AX trials
  • The current study addresses the feasibility and psychometric properties of the AX-CPT and N-Back in a multi-site trial, we did not observe an effect of the investigational drug
  • Dr Richard Keefe currently or in the past 3 years has received honoraria, served as a consultant, speaker, or advisory board member for Abbvie, Acadia, Aeglea, Akebia, Akili, Alkermes, Allergan, ArmaGen, Astellas, Avanir, AviNeuro/ChemRar, Axovant, Biogen, Boehringer-Ingelheim, Cerecor, CoMentis, Critical Path Institute, FORUM, Gammon Howard & Zeszotarski, Global Medical Education, GW Pharmaceuticals, Intracellular Therapeutics, Janssen, Kempharm, Lundbeck, Lysogene, MedScape, Mentis Cura, Merck, Merrakris Therapetics, Minerva Neurosciences Inc., Mitsubishi, Montana State University, Monteris, Moscow Research Institute of Psychiatry, Neuralstem, Neuronix, Novartis, NY State Office of Mental Health, Orygen, Otsuka, Paradigm Testing, Percept Solutions, Pfizer, Pharm-Olam, Regenix Bio, Reviva, Roche, Sangamo, Sanofi, SOBI, Six Degrees Medical, Sunovion, Takeda, Targacept, Teague Rotenstreich Stanaland Fox & Holt, Thrombosis Research Institute, University of Moscow, University of Southern California, University of Texas Southwest Medical Center, WebMD, and Wilson Therapeutics

Need more features? Save interactive summary cards to your Scholarcy Library.